Drive down elevated IGF-1 and GH levels
In two studies, Somatuline® Depot (lanreotide) Injection demonstrated proven reductions in IGF-1 and GH levels.
At the end of studies 1 and 2, there was an overall reduction in IGF-1 and GH levels.1*
Go for normalized IGF-1 and GH levels
58% of patients had normalized IGF-1 levels at the end of 52 weeks.1*
In addition, 69% of patients had GH levels ≤5.0 ng/mL at the end of study.1*
* Study 1: A 52-week study of 108 patients with acromegaly. Qualified patients were randomized to receive a single deep subcutaneous injection of placebo or Somatuline® Depot (lanreotide) Injection 60 mg, 90 mg, or 120 mg, followed four weeks later by a fixed-dose phase where they received four injections of Somatuline® Depot (lanreotide) Injection, and ending in a dose-titration phase where they received eight injections of Somatuline® Depot (lanreotide) Injection. Injections were given at four-week intervals, and during the dose-titration phase, the dose was titrated twice (every fourth injection), as needed, according to individuals GH and IGF-1 levels. 99 patients completed the dose-titration phase of the study. Final values were calculated by carrying forward the last observation from the 107 patients that participated in the dose-titration phase.
Study 2: A 48-week open-label, uncontrolled multicenter study that enrolled 63 patients who had an IGF-1 concentration ≥1.3 times the upper limit of the age-adjusted normal range. In the fixed-dose phase, patients received four deep subcutaneous injections of Somatuline® Depot (lanreotide) Injection 90 mg at four-week intervals. Patients then entered a dose-titration phase where the dose of Somatuline® Depot (lanreotide) Injection was adjusted based on GH and IGF-1 levels at the beginning of the dose-titration phase and, if necessary, again after another four injections. Patients titrated up to the maximum dose (120 mg) were not allowed to titrate down again. 57 patients completed the dose-titration phase of the study. Final values were calculated by carrying forward the last observation from all 63 patients.
